October 8, 2015 Synthetic Biologics Initiates Second SYN-010 Phase 2 Clinical Trial Intended to Treat Irritable Bowel Syndrome with Constipation (IBS-C)
October 1, 2015 Synthetic Biologics Appoints Raymond Stapleton, PhD, as Senior Vice President, Manufacturing
September 21, 2015 Synthetic Biologics Reports First Analysis Demonstrating SYN-004's Ability to Protect the Microbiome from Damage Caused by IV Antibiotics in a Humanized Pig Model
August 10, 2015 Synthetic Biologics Reports Second Quarter 2015 Financial Results and Operational Highlights
August 10, 2015 Intrexon and Synthetic Biologics Enter ECC to Develop Novel Biotherapeutics for Treatment of Phenylketonuria
July 21, 2015 Synthetic Biologics Announces Closing of Recent Equity Offering and Exercise in Full of Underwriters' Over-Allotment Option
